Christine Mazzola
Family · Newark, DENPI 1669471314
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 439 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,009, 3.5 times the $581 reported in 2021. Among family clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 439 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- AstraZeneca$697
- GSK$585
- Abbott$420
- Lilly USA, LLC$369
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,444100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 72 | $1,406 |
| Novo Nordisk | 103 | $1,396 |
| AstraZeneca | 32 | $697 |
| GSK | 45 | $585 |
| Abbott | 23 | $420 |
| Lilly USA, LLC | 21 | $369 |
| Astellas Pharma US Inc | 17 | $311 |
| Pfizer | 16 | $252 |
| Merck | 13 | $240 |
| Otsuka America Pharmaceutical, Inc. | 17 | $231 |
| Boehringer Ingelheim | 10 | $157 |
| Amgen | 8 | $142 |
| Bayer | 6 | $123 |
| Gilead | 4 | $101 |
| Medtronic | 2 | $97 |
| Exact Sciences | 5 | $97 |
| Sanofi-aventis U.S. LLC | 3 | $90 |
| Phathom Pharmaceuticals, Inc. | 5 | $74 |
| Currax Pharmaceuticals LLC | 5 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| VBI Vaccine (delaware) Inc. | 2 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Novartis | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $28 |
| Tactile Systems Technology Inc | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Soleno Therapeutics, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $17 |
How this compares
$7,444 in reported general payments places this provider in the 95th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $24,160 |
| OzempicSemaglutide | 19 | $20,523 |
| MounjaroTirzepatide | 15 | $16,678 |
| JanuviaSitagliptin Phosphate | 13 | $12,611 |
| VascepaIcosapent Ethyl | 12 | $7,063 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 15 | $3,820 |
| Atorvastatin Calcium | 191 | $2,519 |
| Rosuvastatin Calcium | 65 | $1,485 |
| Levothyroxine Sodium | 88 | $1,032 |
| Omeprazole | 57 | $1,011 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $867 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 14 | $754 |
| Olmesartan Medoxomil | 23 | $618 |
| Lisinopril | 47 | $503 |
| Amlodipine Besylate | 50 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet Xr, Januvia | $240 | $36,77130 claims |
| Novo NordiskOzempic | $1,396 | $20,52319 claims |
| Lilly USA, LLCMounjaro | $369 | $16,67815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 523 family providers in Delaware.
Other family in Newark
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Melanie HiesterNewark$9K
- Samatha GrayNewark$9K
- Byron MayNewark$8K
- Clare MatisNewark$8K
- Kelsey FrybergerNewark$7K
- Colleen AllenNewark$7K
- Mallory KowalskiNewark$7K
- Palak DesaiNewark$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.